Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06
在DESTINY-Breast06研究中,对PATHWAY HER2 (4B5)检测方法进行分析和临床验证,以评估HER2低表达/HER2超低表达状态以及患者是否适合接受曲妥珠单抗德鲁替康治疗。
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105310
Shami, R; Salgado, R; Bardia, A; Curigliano, G; Hu, X; Dent, R; Pierga, J-Y; Tsurutani, J; Wildiers, H; Ricciardi, G; Marchiò, C; Penault-Llorca, F; Bor-Angelier, C; Manoogian, M; Lucas, S; Olson, M T; Liu, X; Toro, P; Baker, A F; Fang, Q; Su, J; Yoder, A; Andrzejuk-Ćwik, A; Darilay, A; Matsuo, T; Jones, F; Viale, G